Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
2.150
+0.040 (1.90%)
Oct 11, 2024, 4:00 PM EDT - Market closed

Company Description

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases.

Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.

In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.

The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors.

Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Senti Biosciences, Inc.
Senti Biosciences logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 48
CEO Timothy Lu

Contact Details

Address:
2 Corporate Drive, First Floor
South San Francisco, California 94080
United States
Phone 650 239 2030
Website sentibio.com

Stock Details

Ticker Symbol SNTI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001854270
CUSIP Number 81726A100
ISIN Number US81726A1007
Employer ID 86-2437900
SIC Code 2836

Key Executives

Name Position
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder, Chief Executive Officer and Director
Dr. Kanya Rajangam M.D., Ph.D. President, Head of Research and Development and Chief Medical Officer
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board and Independent Director
Dr. Wilson Wong Ph.D. Scientific Co-Founder and Member of Scientific Advisory Board
Yvonne Li M.B.A. Interim Chief Financial Officer, Treasurer and Principal Accounting Officer
Thomas P. Chung Vice President of Strategic Finance and Corporate Development
Dee Olomajeye Dragon Vice President of People Strategy and Culture

Latest SEC Filings

Date Type Title
Sep 27, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Jul 17, 2024 8-K Current Report
Jul 16, 2024 8-K Current Report
Jul 12, 2024 8-K Current Report
May 29, 2024 ARS Filing
May 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 29, 2024 DEF 14A Other definitive proxy statements
May 17, 2024 PRE 14A Other preliminary proxy statements